All posts

Buy Kinaxis on the dip, says ATB Capital

A “sort-of” miss on quarterly revenue may put pressure on Kinaxis (Kinaxis Stock Quote, Charts, News, Analysts, Financials TSX:KXS) shares, but savvy investors should take it as an opportunity to buy a company with still plenty of tailwinds in the supply chain management space. That’s the scoop from ATB Capital Markets analyst Martin Toner, who reviewed Kinaxis’ fourth quarter results in a client update on Wednesday where he reiterated an “Outperform” rating and kept at 12-month target price of C$200.

Ottawa-based supply chain management platform Kinaxis reported its Q4 2022 financials after market close on Wednesday, featuring consolidated revenue up 43.8 per cent year-over-year to $98.5 million. The topline missed the consensus estimate of 99.4 million but was a beat of the ATB estimate of $97.6 million. (All figures in US dollars except where noted otherwise.)

Gross profit of $61.3 million was also a miss of the Street’s $62.9 million but a beat of ATB’s $60.5 million estimate, while adjusted EBITDA was up a full 87 per cent to $21.1 million beating both the consensus at $13.5 million and ATB at $9.6 million.

Looking ahead, management guided for 2023 revenue of $420-$430 million, which was above the consensus forecast of $416.5 million. Kinaxis sees its SaaS revenue growing by between 25 and 27 per cent over the year, with adjusted EBITDA expected to come in between $55 and $65 million.

“Kinaxis finished the year with clear signs of momentum in the business. We exceeded our initial total revenue and adjusted EBITDA targets despite currency headwinds, grew our customer base by 40 per cent, and achieved Rule of 402 performance,” said John Sicard, President and CEO, in a press release.

Digging into the details, Toner said the fourth quarter SaaS revenue of $58.8 million was up 25.6 per cent year-over-year, in-line with consensus, and he noted management’s medium-term target for SaaS revenue growth of 30 per cent, with EBITDA margin at 25 per cent.

“Kinaxis continues to benefit from secular tailwinds around supply chain management. The Company also continues to invest in what it believes is a significant opportunity,” said Toner.

“Given that opportunity and the well-known cycle of subscription term license revenue, we do not believe 2023 adjusted EBITDA margin guidance below consensus should concern investors. We would view weakness in the shares as a buying opportunity,” he wrote.

At press time, Toner’s C$200 target represented a projected one-year return of 25.8 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: kxs
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

12 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

18 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

19 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

20 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago